Drugs / VANGLUSAGENE ENSIPARVOVEC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04093349 | Oct 2020 → Apr 2032 expected | glycogen storage disease due to acid maltase deficiency, late-onset | Spark Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VANGLUSAGENE ENSIPARVOVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095467 ↗ |
| Known as | SPK-3006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093349 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated viral (AAV) vector” NCT04093349 ↗ |
| Route | Intravenous | “single intravenous infusion of SPK-3006” NCT04093349 ↗ |